NK NantKwest Inc.

6.26
-1.09  -15%
Previous Close 7.35
Open 7.39
Price To Book 4.54
Market Cap 615,778,572
Shares 98,367,184
Volume 4,250,967
Short Ratio
Av. Daily Volume 1,831,683
Stock charts supplied by TradingView

NewsSee all news

  1. Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference

    Complete Responses Noted in Multiple Tumor Types (including Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer, Merkel Cell Cancer, Bladder Cancer, and Non-Hodgkin's Lymphoma) when Natural Killer

  2. NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein

    World's first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete

  3. ImmunityBio to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Company Chairman and CEO to Present Clinical Status Report on QUILT Cancer Breakthrough 2020 Trials in Multiple Tumor Types and Data Update on the Company's N-803 IL-15 Superagonist, which Recently

  4. NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS

    World's first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activation Ongoing durable complete responses ranging from 8 to 11 months

  5. NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers

    First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations of CAR-T therapies for solid

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

90% Disease Control with Median Overall Survival of 9.5 Months - noted - November 7, 2018.
haNK
Pancreatic cancer vaccine
Phase 1/2 ongoing.
haNK
Pancreatic cancer vaccine
80% Disease Control noted - November 7, 2018.
haNK
Triple Negative Breast Cancer (TNBC)
First dosing announced October, 2017.
haNK
Solid tumors
Phase 2 ongoing.
aNK
Merkel cell carcinoma
Phase 2 data noted 2/7 responses (1 PR / 1 CR) - November 7, 2019.
haNK + avelumab + N-803
Merkel cell carcinoma (MCC)
Phase 1b data noted ORR 67% at SABCS December 13, 2019.
haNK + other vaccines (NANT vaccine)
Triple Negative Breast Cancer
IND clearance announced June 5, 2019.
CD19-t-haNK
B-cell lymphoma
Phase 1b data at ASCO 2019 - ORR of 58%, CR rate of 33%.
Nanatinostat (VRx-3996) and valganciclovir
Epstein-Barr Virus Associated Lymphoma
Phase 1 preliminary data noted one complete response - January 14, 2020. Data from the full 11 metastatic pancreatic patients due in 2020.
PD-L1 t-haNK
Solid tumors

Latest News

  1. Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference

    Complete Responses Noted in Multiple Tumor Types (including Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer, Merkel Cell Cancer, Bladder Cancer, and Non-Hodgkin's Lymphoma) when Natural Killer

  2. NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein

    World's first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete

  3. ImmunityBio to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Company Chairman and CEO to Present Clinical Status Report on QUILT Cancer Breakthrough 2020 Trials in Multiple Tumor Types and Data Update on the Company's N-803 IL-15 Superagonist, which Recently

  4. NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS

    World's first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activation Ongoing durable complete responses ranging from 8 to 11 months

  5. NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers

    First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations of CAR-T therapies for solid

  6. NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors

    NantKwest, Inc. (NASDAQ:NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and

  7. NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019

    Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety NantKwest Inc. (NASDAQ:NK), a next generation,